glp-1 drugs retatrutide Retatrutide, an experimental weight-loss drug, has not been approved by the FDA. But, doctors and nurse practitioners in clinics across the country are prescribing it anyway, a CBS News investigation GLP-1 Medications for Weight Loss:

April 18, 2026 Drugs Consultative Committee 68th meeting flags surrogate advertising of GLP-1 obesity drugs state regulators directed to enforce Medical Dialogues March 24, 2026 CDSCO tightens checks on generic semaglutide bans promotional activity, intensifies pharmacy surveillance Business Standard March 21, 2026 Patent expiry Day 1 8+ manufacturers launch simultaneously, prices fall up to 90% from branded versions CNBC March 17, 2026 ZydusLupin and ZydusTorrent licensing agreements announced ahead of patent expiry Pearce IP February 2026 Natco Pharma receives CDSCO approval for generic semaglutide Eris Lifesciences to commercialise Fierce Pharma December 2025 Sun Pharma receives first DCGI approval for generic semaglutide in India Noveltreat and Sematrinity Sun Pharma PR REGULATORY FRAMEWORK CDSCO Standards & Approval Requirements in India India's Central Drugs Standard Control Organisation (CDSCO) is the national drug regulator equivalent to the US FDA

The weight loss timeline for GLP-1 peptides gives you a reference for expected progress rates

Telehealth is available for the Wellness Membership, while GLP-1 patients are monitored through regular in-person visits and weigh ins

[DOI] [PMC free article] [PubMed] [Google Scholar] 198.Lin S, Faust L, Robles-Granda P, Kajdanowicz T, Chawla NV

These observations are consistent in individuals with impaired glucose tolerance, where a single dose of the GLP-1R agonist exendin-4 reduced postprandial plasma TG, ApoB48, and remnant lipoprotein cholesterol and TG [47]

[DOI] [PubMed] [Google Scholar] 131.Jones K.L., Rigda R.S., Buttfield M.D.M., et al